Ulcer Clinical Trials

500 recruitingLast updated: June 13, 2026

There are 500 actively recruiting ulcer clinical trials across 71 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1, Early Phase 1. Top locations include New York, New York, United States, Miami, Florida, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Ulcer Trials at a Glance

500 actively recruiting trials for ulcer are listed on ClinicalTrialsFinder across 6 cities in 71 countries. The largest study group is Not Applicable with 192 trials, with the heaviest enrollment activity in New York, Miami, and Houston. Lead sponsors running ulcer studies include Takeda, AbbVie, and Eli Lilly and Company.

Treatments under study

About Ulcer Clinical Trials

Looking for clinical trials for Ulcer? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ulcer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ulcer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 500 trials

Recruiting
Phase 3

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis
Sanofi671 enrolled40 locationsNCT07185009
Recruiting

Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease

IBD (Inflammatory Bowel Disease)Ulcerative Colitis (UC)Crohn Disease (CD)
Shmuel Kivity, MD40 enrolled1 locationNCT07644117
Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Ulcerative ColitisColitis Ulcerative
Merck Sharp & Dohme LLC100 enrolled9 locationsNCT07463183
Recruiting
Phase 1Phase 2

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Ulcerative Colitis (UC)
Xencor, Inc.270 enrolled66 locationsNCT06619990
Recruiting
Phase 3

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Ulcerative Colitis
Alfasigma S.p.A.80 enrolled47 locationsNCT06865417
Recruiting
Phase 1

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

Ulcerative ColitisUlcerative Colitis ChronicUlcerative Colitis Chronic Mild+1 more
Rise Therapeutics LLC36 enrolled5 locationsNCT05666960
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 2Phase 3

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Colitis Ulcerative
Bristol-Myers Squibb120 enrolled90 locationsNCT05076175
Recruiting

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

Crohn DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag A.G., Switzerland50 enrolled1 locationNCT07532213
Recruiting
Phase 4

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Crohn's DiseaseUlcerative Colitis
Takeda400 enrolled100 locationsNCT06581328
Recruiting
Phase 3

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Colitis UlcerativeArthritis, PsoriaticCrohns Disease+1 more
Janssen Research & Development, LLC196 enrolled47 locationsNCT06663332
Recruiting
Not Applicable

Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers

Diabetic Foot Ulcer
University of New Mexico60 enrolled1 locationNCT04791449
Recruiting
Phase 2Phase 3

Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis

Ulcerative Colitis, Unspecified
University Hospital Schleswig-Holstein459 enrolled26 locationsNCT06488625
Recruiting
Phase 4

The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass

ObesityGastric refluxUlcer, Gastric
Prof Urs Zingg50 enrolled1 locationNCT05320796
Recruiting
Not Applicable

AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis

ColitisUlcerative Colitis (UC)Inflammatory Bowel Disease (IBD)
ENBIOSIS BIOTECHNOLOGIES162 enrolled1 locationNCT07619638
Recruiting
Phase 2

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Ulcerative Colitis
Pfizer36 enrolled46 locationsNCT05287126
Recruiting

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag G.m.b.H500 enrolled1 locationNCT07102368
Recruiting
Phase 3

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled393 locationsNCT07196748
Recruiting
Phase 1Phase 2

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

Moderate to Severe Ulcerative Colitis
Genentech, Inc.24 enrolled1 locationNCT06693908
Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag Ltd.220 enrolled1 locationNCT07242248